Using Sodium Valproate in Children <2 Years of Age: Study in a District Hospital, Dinajpur, Bangladesh

Dr. Md. Mostafa Zaman1,*, Md. Saiful Islam2, Sougata Mitra3, Md. Zakaria4, Md. Tazul Islam5

1Department of Paediatrics, Rangpur Medical College Hospital, Rangpur, Bangladesh
2Department of Radiology and Imaging, Rajshahi Medical College Hospital, Rajshahi, Bangladesh
3Department of Pharmacology and Therapeutics, Pabna Medical College, Pabna, Bangladesh
4Department of Paediatrics, Sunamgong Sadar Hospital, Sunamgong, Sylhet, Bangladesh
5Department of Paediatrics, 250 Bedded General Hospital, Jamalpur, Bangladesh
*Corresponding author: dr.mostafazaman@gmail.com

Received April 03, 2021; Revised May 11, 2021; Accepted May 19, 2021

Abstract

Introduction: Sodium valproate is proposed for addition to the Model List of Essential Medicines, for use in the management of epilepsy in children. This is effective in treating many seizure types, like a generalized tonic-clonic seizure, myoclonic seizure, absence seizure, in other epilepsy syndromes like an infantile spasm, Landau-Kleffner syndrome (LKS), etc. Aim of the study: This study aimed to observe the side effects caused by sodium valproate in children below 2 years of age. Methodology: An observational study was conducted in the Department of Paediatric M Abdur Rahim Medical College (MARC), Dinajpur, Bangladesh, during the period of January 2019 to December 2019. Sixty (60) children < the age of years with epilepsy were enrolled in this study. Enrollment was done after informed verbal consent from the mother or the attendant. Detail history was taken about demographic factors which include children’s age, age of onset of seizure, height, weight. Data were collected in a pre-designed questionnaire. The data was processed and analyzed by the application of SPSS version-22.

Results: Male were dominated the gender distribution and were 54% and female were 46%. A maximum of 46% of patients was diagnosed with epilepsy between 6-12 months, Out of the total studied patients, the maximum 44% started sodium valproate ages between 7 -12 months. Among the total studied patients 40% took 26-30mg/kg/day sodium valproate as their treatment regime. A total of 16% had anemia among the studied patients, whereas for the rest 84% of patients no other symptoms were found during their general examination. Among the total studied patients, the most dominating side effect of the patients was vomiting which resulted in 1/5th (20%) of all side effects. The side effects of both hair loss and loss of appetite show the same result of 10% for each whereas, only 4% and 2% had abdominal pain and weight gain respectively. Conclusion: In this study vomiting was found as the most significant side effect which similar to other different studies also. These findings may be helpful for future researchers in further research. It was a single centered study with a small-sized sample.

Keywords: epilepsy, anti-epileptic drug, sodium valproate

Cite This Article: Dr. Md. Mostafa Zaman, Md. Saiful Islam, Sougata Mitra, Md. Zakaria, and Md. Tazul Islam, “Using Sodium Valproate in Children <2 Years of Age: Study in a District Hospital, Dinajpur, Bangladesh.” American Journal of Medical Sciences and Medicine, vol. 9, no. 2 (2021): 48-52. doi: 10.12691/ajmsm-9-2-3.

1. Introduction

Sodium valproate is effective in controlling tonic-clonic seizures, particularly in primary generalized epilepsy. It is used to control seizures (fits) in most types of epilepsy. Sodium valproate may be used alone or in combination with another anticonvulsant for the treatment of epilepsy. Sodium valproate may take several days to show an initial effect and in some cases may take two to six weeks for the maximum effect. Treatment is started with low doses and may be increased over a couple of weeks according to the response. This is effective in treating many seizure types, like a generalized tonic-clonic seizure, other types of generalized epilepsy like a myoclonic seizure, absence seizure, in other epilepsy syndromes like an infantile spasms, severe myoclonic epilepsy (SME), Landau – Kleffner syndrome (LKS), myoclonic-astatic epilepsy (MAE), etc. Sodium Valproate has rare but severe side effects on the liver, bone marrow, and pancreas [1]. Most Sodium Valproate hepatotoxicity occurred in children younger than 2 years who had preexisting neurological or other physical defects [2]. Special precaution should be needed for its use in children below 2 years of age and children treated with multiple anti-epileptic drugs (AEDs). Sodium valproate is an anticonvulsant. Epilepsy is a common neurological disorder that demands immediate medical attention and often long term therapy. Sodium valproate is one of the most potent drugs with a broad
sodium valproate therapy. Epilepsy is a common neurological disorder that demands immediate medical attention and often long term therapy. A high prevalence of epilepsy in children is frequently found in developing countries [6]. There are situations where sodium valproate is absolutely indicated where other potential anticonvulsants are not available or costly that includes west syndrome, severe myoclonic epilepsy, myoclonic-astatic epilepsy (MAE). There is no need of monitoring the drug level of the sodium valproate therapy. Sodium valproate achieved a high degree of seizure control with 75% of patients having at least 12 months of freedom free seizures [5]. This current study attempts to analyze the pattern of side effects after using the sodium valproate in children under 2 years of age with epilepsy and their impact on the continuation of sodium valproate therapy.

2. Objectives

General Objective
To observe the effect of using sodium valproate in children below 2 years of age.

3. Materials and Methods

This study was an observational cross-sectional study conducted in the department of Paediatric M Abdur Rahim Medical College (MARMC), Dinajpur, Bangladesh, during the period of January 2018 to December 2018. The total duration of the study was 1 year and for the first time, the population size was roughly estimated at 60. As per the sample estimation formula if \( N \) would be less than 10,000 the required sample size would be smaller. In that case final sample was estimated (nf) by using the following formula and according to the formula the estimated final sample size was 60. The sampling method was consecutive.

Inclusion criteria: Children with epilepsy of both sexes under 2 years of age, who prescribed sodium valproate as immunotherapy.

Exclusion criteria: Children with status epileptics and seizures associated with acute conditions like stroke are excluded. Patients with pre-existing status epileptics, bone marrow abnormalities, and neuro-metabolic diseases were also excluded.

4. Results

Sodium Valproate is rarely used in cases of epilepsy below 2 years of age. That is why the target group was small in size and only 60 children having epilepsy was seen and investigated in the data-gathering period. In this study, the proportion and pattern of side effects were observed in 60 cases of children of epilepsy, who were prescribed sodium valproate by the attending physician of the study center. Study results have shown below in the tabulated and graphic form.

Table 1. Among the total study patients, the minimum and maximum age of them was 6 months and 36 months respectively, the mean±SD age was 15.88±6.81 months. In relation to the onset of a seizure, the minimum and maximum age of the patients were 2 and 20 months respectively and their mean±SD age was 8.3±4.99 months. It also revealed that the minimum and maximum weights were 7 kg and 14 kg respectively, the mean±SD weight was 10.26±1.66 kg. The study also revealed that the minimum and maximum height of the patients was 65 cm and 93 cm respectively and the mean±SD height was 76.8±7.02 cm. The sex composition of the study patients was presented in Figure 1. Results revealed that the sex ratio of male to female was 1:1.17.

Table 2 showed the age at diagnosis of the patients, which point out that the maximum 46% of patients were diagnosed between 6-12 months, 28% patients below 6 months, and the rest 26% patients were range between 12-24 months. Table 3 showed the dose of sodium valproate among studied patients. Among the total studied patients 40% took 26-30mg/kg/day of sodium valproate, 32% patients took 20-25 mg/kg/day, 20% took 31-35 mg/kg/day of sodium valproate and only 8% took 36-40 mg/kg/day of sodium valproate. Table 4 illustrated that out of the total 60 patients 74% had GTCS, 12%, and 14% had Myoclonic epilepsy and infantile spasm respectively. Table 5 illustrated the type of investigations done for the patients. Out of the total studied patients, the minimum and maximum percentages for HB were 9% and 12.2% respectively, whereas their mean percentage for HB was 11.18±0.70. Regarding the ESR the minimum and maximum investigations were 6 mm in the 1st hour and 25 mm in the 1st hour respectively, whereas their mean investigation for ESR was 12.54±4.26. The investigation for TC of WBC showed that the minimum and maximum
count were 5.5X10^9/L and 13X10^9/L respectively, whereas the mean count for TC of WBC was 12.54±4.26. In relation to the percentage for Neutrophil illustrated that the minimum and maximum percentages were 22% and 59% respectively, whereas their mean percentage for Neutrophil was 46.4±6.45. The investigation for Lymphocytes showed that the minimum and maximum percentages were 40% and 60% respectively, whereas the mean percentage for lymphocytes was 49.82±4.9. In regard to the Monocyte, the maximum percentage was 10%, whereas there was no minimum result for Monocyte percentage and their mean percentage for Monocyte was 2.54±1.86. The percentage for Eosinophil showed that the minimum and maximum percentage among the total respondents were 2% and 7% respectively, whereas their mean percentage for Eosinophil was 3.13±1.81. In regard to the Platelet, the minimum and maximum count among the 49 studied patients out of 60 were 210X10^9/L and 410X10^9/L respectively, whereas the mean number for Platelet was 287.14±35.92. This table also revealed that the investigation for Serum ammonia among the total patients results that the minimum and maximum levels were 21 micromole/L and 63micromole/L respectively, whereas the mean level for Serum ammonia was 43.1±9.68. The level for Serum SGPT showed that the minimum and maximum levels were 15 U/L and 35 U/L respectively, whereas their mean level for Serum SGPT was 25.08±5.29. Table 6 showed the side effect of the sodium valproate of the studied patients. Among the total studied patients, the most common side effect was vomiting which resulted in 1/5th (20%) of all side effects. The side effects of both hair loss and loss of appetite showed the same result of 10% for each whereas, only 4% and 2% had abdominal pain and weight gain respectively. No patient had clinical, serological, or sonological evidence of pancreatitis and hepatic impairment. Table 7 showed the association between side effects of sodium valproate with a type of epilepsy. Among the total studied patients, 20% had vomiting which is a common side effect in all types of epilepsy. The trend of this result is almost the same for both hair loss and loss of appetite of 10% for each side effect that holds all types of epilepsy. In addition, this table also revealed that the side effects of both weight gain and abdominal pain were contained by only one type of epilepsy out of three i.e., infantile spasm for weight gain, whereas GTCS for abdominal pain. The 2 cases of abdominal pain were further evaluated by USG of HBS.

Table 1. Descriptive statistics of some demographic characteristics of the patients (N=60)

| Demographic characteristics | Minimum | Maximum | Mean   | SD    |
|----------------------------|---------|---------|--------|-------|
| Age of patient (months)    | 6       | 36      | 15.88  | 6.81  |
| Age at onset of seizure (month) | 2    | 20      | 8.3    | 4.99  |
| Weight (Kg)                | 7       | 14      | 10.26  | 1.66  |
| Height (cm)                | 65      | 93      | 76.82  | 7.02  |

Table 2. Distribution according to age at diagnosis (n=60)

| Age at diagnosis | Frequency | Percentage (%) |
|------------------|-----------|----------------|
| < 6 months       | 17        | 28.33          |
| 6-12 months      | 27        | 45.0           |
| 12-24 months     | 16        | 26.66          |
| Total            | 60        | 100.0          |

Table 3. Distribution of the patients by the dose of sodium valproate (n=60)

| Dose (mg/kg) | Frequency | Percentage (%) |
|--------------|-----------|----------------|
| 20-25 mg     | 19        | 31.66          |
| 26-30 mg     | 24        | 40.0           |
| 31-35 mg     | 12        | 20.0           |
| 36-40 mg     | 5         | 8.33           |
| Total        | 60        | 100.0          |

Table 4. Distribution of the patients by types of epilepsy (n=60)

| Types of epilepsy | Frequency | Percentage (%) |
|-------------------|-----------|----------------|
| GTCS              | 44        | 73.33          |
| Infantile spasm   | 9         | 15             |
| Myoclonic epilepsy| 7         | 11.66          |
| Total             | 60        | 100.0          |

Table 5. Descriptive statistics of different types of Investigations sought by the patients (n=60)

| Investigations     | N   | Minimum | Maximum | Mean  | Std. Deviation |
|--------------------|-----|---------|---------|-------|----------------|
| Hb (%)             | 60  | 9.00    | 12.20   | 11.18 | 0.70           |
| ESR (mm in 1st hour) | 60  | 6.00    | 25.00   | 12.54 | 4.26           |
| TC of WBC (10^9/L) | 60  | 5.50    | 13.00   | 7.77  | 1.58           |
| Neutrophil (%)     | 60  | 22.00   | 59.00   | 46.40 | 6.45           |
| Lymphocyte (%)     | 60  | 40.00   | 60.00   | 49.82 | 4.90           |
| Monocyte (%)       | 60  | 0.00    | 10.00   | 2.54  | 1.86           |
| Eosinophil (%)     | 9   | 2.00    | 7.00    | 3.13  | 1.81           |
| Platelet (10^9/L)  | 59  | 210.00  | 410.00  | 287.14| 35.92          |
| Serum ammonia (micromole/L) | 60 | 21.00   | 63.00   | 43.10 | 9.68           |
| Serum SGPT (U/L)   | 60  | 15.00   | 35.00   | 25.08 | 5.29           |
Table 6. Distribution according to side effects of the patients (n=60)

| Side effects   | Frequency | Percentage (%) |
|----------------|-----------|----------------|
| Vomiting       | 12        | 20.0           |
| Hair loss      | 6         | 10.0           |
| Weight gain    | 1         | 1.66           |
| Abdominal pain | 2         | 3.33           |
| Loss of appetite | 6   | 10.0           |
| No Side Effects | 33       | 55.0           |

Table 7. Association of side effects of sodium valproate with types of epilepsy (n=60)

| Side effects   | Types of epilepsy | Total |
|----------------|-------------------|-------|
|                | GTCS              | Infantile spasm | Myoclonic epilepsy |
| Vomiting       | 6(10.0%)          | 1(1.66%)        | 4(6.66%)           | 12(20%) |
| Hair loss      | 4(6.66%)          | 1(1.66%)        | 1(1.66%)           | 6(10.0%) |
| Weight gain    | 0                 | 1(1.66%)        | 0                  | 1(1.66%) |
| Abdominal pain | 2(3.33%)          | 0               | 0                  | 2(3.33%) |
| Loss of appetite | 4(6.66%)  | 1(1.66%)        | 1(1.66%)           | 6(10.0%) |

5. Discussion

Seizures have been found to have a higher incidence in younger children with a decreasing frequency in the older age group [8,9]. In childhood epilepsy, the common age at diagnosis is 1 month to 5 years observed in a study [10], but in this study, epilepsy has been frequently found at the age of 6months to 1 year. In many studies, seizures are found to be more common in males [8,9]. This may have happened due to a lack of representativeness of the sampled population between the two studies or research design. To control the seizures maximum dose used here was 40mg/kg/day of sodium valproate whereas a maximum dose of 30mg/kg/day was received by patients in other similar studies [13]. There was another study that showed the daily dosage of sodium valproate was 30-50 mg/kg body weight in childhood epilepsy [11]. There are different types of epilepsy found in different age groups. In this study, most of the patients presented with GTCS (73.33%), and the second most was infantile spasm (15%). On the other hand, generalized tonic-clonic (61%), focal seizure (33%), and miscellaneous seizures (6%) were found in other studies. It was observed that GTCS is the most common type of epilepsy in childhood [13]. Thrombocytopenia is one of the side effects of valproate therapy [14]. In some studies, it was observed that thrombocytopenia occurred in the study populations [15] patients had thrombocytopenia out of 45 patients). Thus, immune-mediated thrombocytopenia may be a common accompaniment of the administration of valproic acid, but the pathogenesis of this phenomenon remains to be explored [14]. However, this study didn’t observe any case of thrombocytopenia with valproate therapy. Regarding metabolic disturbances, hyperammonemia is seen with VPA therapy, as a consequence of increased renal production of ammonia or inhibition of nitrogen elimination or both [16,17]. Hyperammonemia may be enhanced in the presence of poly-therapy [18,19]. However, this study didn’t observe any case of hyperammonemia with valproate therapy. Along with some rare side effects, there are some common side effects in valproate therapy. In this study, among 60 patients, there were some milder side effects found such as vomiting (n=12), weight gain (n=1), hair loss (n=6), and loss of appetite (n=6). Similarly, another study conducted a retrospective analysis of 100 children with epilepsy treated with sodium valproate and found some milder but troublesome side effects which were increased weight gain (n=44), gastrointestinal disturbances (n=20), transient hair loss (n=6) [11]. In addition, 211 epileptic patients in a study were given sodium valproate as a single drug treatment. During the course of therapy, six cases of hair loss were found between sodium valproate users [7]. Though the studies had different sample sizes the findings were quite similar, especially the gastrointestinal disturbances and hair loss. Hepatotoxicity is a rare but very serious side effect in valproate therapy. High incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects and the incidence of fatal hepatic failure associated with valproic acid (VPA) therapy is found to be highest in children under the age of three years, particularly in those with developmental delay. Moreover, most cases of VPA hepatotoxicity occurred in children younger than 2 years who had preexisting neurologic or other physical defects. Many were developmentally delayed. A precipitating illness, possibly viral, occurred in many children [20]. However, our study did not find any valproate hepatotoxicity among the studied children. Acute pancreatitis is another serious side effect of valproate therapy. In this study, no cases of acute pancreatitis were observed. Similarly, another study was conducted and it was found that there is a definitive association between valproate therapy and acute pancreatitis. They found only 2 cases of Valproate associated pancreatitis described below 2 years of age. Though the definite association between valproate and acute pancreatitis has been reported, the underlying etiology is still unknown [21]. Considering the various studies around the use of Sodium Valproate including the current one has stated that there was no significant incidence of side effects with the exception of patients who developed vomiting, hair loss, loss of appetite, and weight gain. No hepatic and pancreatic impairment was found due to the use of sodium valproate in treating epilepsy of children under 2 years of age. The average annual incidence of epilepsy in developed countries is 40-70 per 100,000 of the general population. In developing countries, this figure is much higher at around 100-190 per 100,000 of the general population per year [22]. Though high rates of acquired brain injury may contribute, the possibility that malnutrition may lower seizure threshold has rarely been examined. This review suggests potential biochemical mechanisms that could adversely affect seizure threshold, particularly the effect of malnutrition on inhibitory neurotransmitters and electrolyte imbalance [19]. Most Sodium Valproate hepatotoxicity occurred in children younger than 2 years who had preexisting neurological or other physical defects. Special precaution should be needed for its use in children below 2 years of age and children treated with multiple anti-epileptic drugs (AEDs) [19]. Various clinical studies over the last decades have demonstrated that VPA is effective in the treatment of many seizure types, including absence, tonic-clonic, and partial seizures. Both as add-on therapy and as monotherapy VPA is well-established as a first-line drug.
In addition, it is also used to treat infantile spasms (West syndrome), Lennox-Gastaut syndrome, febrile seizures, and status epilepticus [1]. A micro-dialysis study in humans demonstrated the pharmacokinetic rationale for acute treatment with VPA. It is based on the rapid distribution of VPA to the brain [2]. Recently, Marson et al. performed a meta-analysis that compares VPA with carbamazepine in the monotherapy of epilepsy. The investigators concluded that there was no reason for the preference of VPA for generalized-onset seizures, while the preference for carbamazepine was supported in the case of partial-onset seizures [21]. Gastrointestinal side effects, e.g., nausea, vomiting, and gastrointestinal distress have been reported to occur in up to 25% of the patients, probably less with enteric-coated formulation [1]. Weight gain is a frequent problem, and an increase in body weight probably less with enteric-coated formulation [1]. Weight gain during VPA therapy is associated with metabolic changes like a decrease in Beta-oxidation of fatty acids [23], increased insulin and insulin/glucose ratios, and increased leptin and insulin levels [18]. The problem appears to be more common in females, it is not necessarily eliminated by caloric restriction, and it may lead to discontinuation of VPA therapy [23].

6. Conclusion

In this study ‘vomiting’ was found as the most significant side effect which was similar to other different studies also. These findings may be helpful for future researchers in further research. In fact, it was a single centered study with a small-sized sample. So the findings of this study may not reflect the exact scenario of the whole country.

7. Recommendations

We would like to recommend more studies fociching on epilepsy in children under the age of 2 with larger sized sample for getting appropriate findings.

References

[1] Cecilie U. Johanssens, Svein J. Johanssens. Valproate: Past, Present, and Future. CNS Drug Rev. 2003; 9: 207-209.
[2] Yogita Dawda, Niina Ezewuzie. Epilepsy pharmacological treatment and monitoring. Clinical pharmacist 2010; 2: 89-94.

[3] http://lifeinthestandlane.com/book/critical-care-drugs/sodium-valproate (Accessed date: 02/02/2015).
[4] Appleton RE, Farrell K, Applegarth DA, Dimmick JE, Wong LT, Davidson AG. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci. 1990 May; 17 (2): 145-8.
[5] Ebrahimi H, Shamsadini S, Eskhavar S S. Frequency of Sodium Valproate-Induced Hair Loss and Curly Hair. IJPT 2005; 4: 143-145.
[6] Verity CM, Hosking G, Easter DJ. A multicenter comparative trial of sodium valproate and carbamazepine in Paediatric epilepsy. Dev Med Child Neurol, 1995; 37: 97-108.
[7] Sodium valporate in childhood epilepsy: WHO. November 2006.
[8] Chung B, Wat LC, Wong V. Febrile seizures in southern Chinese children: incidence and recurrent. Pediatr Neurol. 2006 Feb; 34 (2): 121-6.
[9] Saravanan S. profile of children admitted with seizures in a tertiary care hospitals in south India. JOSR-IDMS. 2013; 11(4): 56-61.
[10] J Egger and E M Brett. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed), 1981; 283(6293): 577-581.
[11] Adhikari S, Sathian B, Koirala DP, Rao KS. Profile of children admitted with seizures in a tertiary care hospitals of Western Nepal. BMC Pediatr. 2013; 13: 43.
[12] Coppola G, Auricchio G, Federico R, Carotenuto M, Pasquato A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomised, parallel group study. Epilepsia, 2004; 45(9): 1049-1053.
[13] Springview Cottage, More Hall Lane, Bolsterstone. Epilepsy in rural Ugandan children: seizure pattern, age of onset and associated findings. Afr Health Sci. 2010 Sep; 10(3): 218-225.
[14] Ronald D Barr, Shirley A Copeland, Michelle L Stockwell, Neil Morris, John C Kelton. Valproic acid and immune thrombocytopenia. Archives of Disease in Childhood, 1982; 57, 681-684.
[15] Hjem M, de Silva LV, Seakins JW, Oberholzer VG, Rolles CJ. Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. Br Med J 1986; 292: 23-24.
[16] Honeycutt D, Callahan K, Rutledge L, Wans B, Heterozygotic ornithine transcarbamylase deficiency pre-senting as symptomatic hyperammonemia during initiation of valproate treatment. Neurology 1992; 42: 666-668.
[17] Williams CA, Tiefenback S, McReynolds JW. Valporic acid-induced hyperammonemia in mentally retarded adults. Neurology 1984; 34: 550-553.
[18] Paganini M, Zaccara G, Moroni F, Campostrini R, Bendoni L, Arnetoli G, Zappoli R. Effect of associated anti-epileptic treatment on valproate-induced hyperammonemia. The Drug Monit 1985; 7: 185-190.
[19] Anderson GD, Children versus adults: pharmacokinetic and adverse-effects differences. Epilepsia. 2002; 43 Suppl 3: 53-9.
[20] Ahmad E, Hamad, Mahmoud E. Fawzi. Valproate associated acute pancreatitis. Neurosciences 2000; 5 (3): 156-158.
[21] Scott RA, Lhatoow SD, Sander JWA. The treatment of epilepsy in developing countries: where do we go from here? Bulletin of the WHO 2001; 79(4): 344-351.
[22] Marson A, Tobias B, Sarah J, Marius N, Mauro J et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. PMC 2008; 134(3): 521-533.
[23] Breum L, Astrup A, Gram L. Metabolic changes during treatment with valproate in human: Implications for weight gain. Metabolism 1992; 41: 666-670.

© The Author(s) 2021. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).